Contextual Genomics offers high quality and cost effective Next-Generation Sequencing (NGS) liquid and tissue biopsy cancer genomic tests optimized for clinical actionability and reimbursement
High quality and cost-effective tests.
Contextual Genomics’ cancer genomic tests are best in class clinical grade cancer assays that digitize biologic samples. We develop reimbursable tests that are designed to be inexpensive, medically necessary, allow for rapid scaling, and facilitate the collection of longitudinal patient data by monitoring tumour and blood. Local optimization and validation of the tests occurs within each of our partners facilities. Our cancer genomic tests, suggested operating procedures, and standardized analytics ensures the consistency and quality of the data and derivative clinical reports.
Amplicon Panel Test is designed for next-generation sequencing (NGS) to detect clinically actionable genomic mutations in solid tumor biopsies, including single base substitutions (SNVs), small deletions and insertions of up to 24bp.
FIND IT™ is used to characterize somatic mutations for therapeutic decisions.
Amplicon Panel Test is designed for next-generation sequencing (NGS) to detect clinically actionable genomic mutations in cell-free circulating tumour DNA (ctDNA) in plasma.
FOLLOW IT™ is ideal for patients when tissue biopsy is not an option or as a time series monitoring tool for progression of cancer and/or to detect treatment resistance.
Our End-to-End Workflow
7 day Turnaround Time (TAT) from sample receipt to report generation
We offer a complete End-to-End or “sample-to-report” workflow to our partner labs that guarantees the speed and accuracy of the results. Patients’ privacy is protected as personal information never leaves your local servers.
FIND IT™ : Detecting Mutations in Solid Tumour Tissue
The FIND IT™ Test focuses on clinically actionable mutations in most solid tumour cancers which are treatable with current therapies or Phase 3 investigational treatments. The results of the assay identify therapeutic targets for patients, acquired drug resistance mutations, and mutations with prognostic and diagnostic implications for patient care. The FIND IT™ Test leads to personalized treatment for patients.
The assay is performed on DNA extracted from formalin-fixed paraffin embedded (FFPE) solid tumour cancers. The results of the assay are presented in a comprehensive report that includes histopathology and interpretation of the sequencing results. Interpretation of the results may include matching of mutations with locally approved drugs, review of recommendations from the National Comprehensive Cancer Network (NCCN), review of the literature, and identification of suitable clinical trials.
FIND IT™ focuses on more than 146 hotspots and 23 exons in 30 known cancer genes.
FOLLOW IT™ : Detecting Mutations in Plasma
Early Access Version currently available to partners
The FOLLOW IT™ Test detects mutations in circulating tumour DNA (ctDNA) derived from plasma. Results from FOLLOW IT™ inform patients and oncologists of treatment response and relapse/remission of disease over time.